PENTIXAPHARM HOLDING N AG (XETRA:PTP) — Market Cap & Net Worth
Market Cap & Net Worth: PENTIXAPHARM HOLDING N AG (PTP)
PENTIXAPHARM HOLDING N AG (XETRA:PTP) has a market capitalization of $46.89 Million (€40.11 Million) as of May 4, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #22126 globally and #1957 in its home market, demonstrating a -0.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PENTIXAPHARM HOLDING N AG's stock price €2.02 by its total outstanding shares 24783048 (24.78 Million).
PENTIXAPHARM HOLDING N AG Market Cap History: 2024 to 2026
PENTIXAPHARM HOLDING N AG's market capitalization history from 2024 to 2026. Data shows change from $85.47 Million to $58.53 Million (-39.40% CAGR).
PENTIXAPHARM HOLDING N AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PENTIXAPHARM HOLDING N AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTP by Market Capitalization
Companies near PENTIXAPHARM HOLDING N AG in the global market cap rankings as of May 4, 2026.
Key companies related to PENTIXAPHARM HOLDING N AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PENTIXAPHARM HOLDING N AG Historical Marketcap From 2024 to 2026
Between 2024 and today, PENTIXAPHARM HOLDING N AG's market cap moved from $85.47 Million to $ 58.53 Million, with a yearly change of -39.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €58.53 Million | +36.30% |
| 2025 | €42.94 Million | -49.76% |
| 2024 | €85.47 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of PENTIXAPHARM HOLDING N AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.89 Million USD |
| MoneyControl | $46.89 Million USD |
| MarketWatch | $46.89 Million USD |
| marketcap.company | $46.89 Million USD |
| Reuters | $46.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more